Following injury to the central nervous system, an astroglial scar forms that is thought to impede neuronal regeneration and recovery of function. It is our hypothesis that inflammatory cytokines act upon astrocytes to alter their biochemical and physical properties, which may in turn be responsible for failed neuronal regeneration. We have therefore examined the interactions of two cytokines with prominent actions following injury, interferon-␥ (IFN-␥) and basic fibroblast growth factor (FGF2), in modulating the extracellular matrix and proliferation of astrocytes in culture. We also evaluated the effects of these cytokines on the ability of astrocytes to support the growth of neurites. IFN-␥ significantly inhibited the proliferation of rat cortical astrocytes both in serum-free and serum-containing media as measured by [ 3 H]thymidine incorporation. Furthermore, IFN-␥ also antagonized FGF2-induced proliferation. In parallel, IFN-␥ reduced the levels of the ECM molecules tenascin, laminin, and fibronectin as evaluated by Western blot analysis and immunocytochemistry. Similarly, IFN-␥ also antagonized FGF2-induced tenascin formation. While IFN-␥-pretreated astrocyte monolayers did not differ from control in their ability to support neurite outgrowth of cortical neurons, it antagonized the enhancement of neurite outgrowth on FGF2-treated monolayers. We demonstrate that IFN-␥ did not alter signal transduction through the FGF2 receptor down to the phosphorylation of mitogen-activated protein kinase, suggesting that the interaction is at the level of transcriptional regulation or that an alternate pathway is involved. These results support the hypothesis that inflammatory cytokines interact to modulate several facets of the gliotic response and such interactions may be important in creating the biochemical and physical properties of the glial scar. 1997 Academic Press
INTRODUCTION
After a traumatic injury to the mammalian central nervous system (CNS), axons within the lesion site fail to regenerate (6, 41) . Axons begin to sprout, but never achieve significant growth toward their targets. This abortive attempt at functional restitution appears not to be based on the intrinsic ability of CNS neurons to regrow since they will extend for considerable distances if given an appropriate substrate (11) . Thus, some intrinsic property of the CNS environment appears to limit regeneration.
The region in which neurites are arrested has been classically described as a glial scar. This tissue is largely composed of a dense network of hypertrophic astrocytes with thick, interdigitating processes and their associated matrices (42) . While it has long been believed that the three-dimensional structure of the astrocytic scar creates a mechanical barrier to regeneration (21, 41) , it has been recently shown that elongating axons still fail to cross a lesion area with a normal glial alignment (12) . Moreover, neurite outgrowth is inhibited on the two-dimensional surface of glial cells growing on nitrocellulose filters removed from implants within the cerebral cortex of adult animals (46) . This suggests that changes in the molecular properties of the glial scar may also play a significant role in the creation of a permissive or inhibitory environment for neuronal regrowth.
Astrocytes are capable of synthesizing a variety of extracellular matrix (ECM) molecules, such as tenascin, laminin, and fibronectin, that have the ability to alter neuritic outgrowth in vitro and in ex vivo culture preparations. ECM components that are expressed prominently during CNS development are downregulated in the adult brain. However, injury to the CNS induces an enhanced expression of these ECM molecules by reactive astrocytes (24, 30, 49) . The degree to which these molecules contribute to enhancement or inhibition of axonal regeneration is still a matter of debate. In vitro assays clearly point to the ability of tenascin, laminin, and fibronectin, as well as other ECM molecules, to dramatically modulate neurite outgrowth (14, 18, 44, 56 ). Yet despite this abundance of information on the expression of these molecules during development and injury, very little is known about their regulation in the CNS after injury.
Cytokines, protein immunomodulators, are believed to be important signals which control structural and functional responses to CNS injury (29) . Following injury to the adult CNS, disruption of the blood-brain barrier results in the recruitment of hematogenous inflammatory cells and the activation of endogenous CNS cells (25, 38) , which provide an abundant source of cytokines. These inflammatory cytokines have been implicated in the process of astrogliosis based on in vitro and in vivo studies, e.g., cell proliferation and glial fibrillary acidic protein (GFAP) expression by astrocytes following exposure to various cytokines, including interleukin-1␤, tumor necrosis factor-␣, transforming growth factor-␤ (TGF-␤), basic fibroblast growth factor (FGF2), and interferon-␥ (IFN-␥) (19, 20, 27, 33, 47, 54) . It thus seems plausible that these same cytokines are also responsible for the alteration in ECM composition noted after injury. Data from our laboratory have previously demonstrated that treatment of cortical astrocyte monolayers with FGF2 enhances the production of tenascin in a dose-dependent manner. Likewise, astrocytes exposed to TGF-␤ up-regulate their synthesis of tenascin (48) , laminin, and fibronectin (2) . Moreover, FGF2 can synergize with TGF-␤ and further enhance the production of tenascin by astrocytes (48) . This suggests that multiple inflammatory cytokines can interact to modulate the ultimate types and levels of ECM molecules found after injury, which then may in turn affect axonal regeneration. In this regard, we have chosen to examine the interaction of FGF2 with IFN-␥, a prominent inflammatory cytokine which has been noted for promoting gliosis in vivo (54) . We find that these molecules interact to regulate both astrocyte ECM production and the ability of astrocytes to support neurite outgrowth. Chemicon (Temecula, CA); polyclonal anti-laminin was from Sigma; monoclonal anti-mitogen-activated protein kinase (clone ZK1.2) was from Zymed (South San Francisco, CA); and horseradish-conjugated polyclonal anti-phosphotyrosine (clone RC20H) was from Transduction Laboratories (Lexington, KY). All other reagents and tissue culture supplies were obtained from Sigma Chemical Co.
MATERIALS AND METHODS

Materials
Astrocyte cultures and treatment with cytokines. Astrocyte cultures were prepared by the method previously described (37) . Cerebral cortices were removed from newborn rats (postnatal days 1-3) and placed into cold BME with 0.02 M Na-Hepes buffer, pH 7.4 (BMEHepes). The meningeal tissue and white matter was removed, and the remaining tissue was minced into fine sections (1 mm) with dissecting knives. The minced sections were incubated with 0.025% trypsin (type-II) for 30 min at 37°C. The reaction was halted with 0.025% soybean trypsin inhibitor and 0.05% DNase I, and the tissue was triturated several times through a fire-polished Pasteur pipette. The suspension was passed through sterile 40-µm nylon mesh cloth to remove large cell aggregates and then centrifuged for 5 min at 1000g. The pellet was resuspended in medium composed of DMEM supplemented with 10% heatinactivated fetal calf serum, NaHCO 3 (2.2 mg/ml), penicillin (50 µg/ml), and streptomycin (50 U/ml) (DMEM/10% FCS). The cells were plated into 80-cm 2 culture flasks (Nunc) and incubated at 37°C in 95%:5% air:CO 2 atmosphere with 100% relative humidity. When the cells become confluent (approximately 14 days), the flasks were shaken overnight (200 rpm) on a rotary shaker to remove loosely adherent cells (neurons, O-2A progenitors, macrophages, and oligodendrocytes). Astrocyte cultures are routinely screened via immunofluorescence techniques for the expression of GFAP as well as for the absence of oligodendrocyte and neuronal markers, and this culture method generally yields Ͼ95% GFAP-positive cells. The astrocytes were subcultured into 6-well culture trays (Falcon) at a density of 2.0 ϫ 10 5 per well for Western blotting or onto poly-L-lysine (PLL)-coated 12-mm round glass coverslips in 24-well trays at a density of 3.5-4.0 ϫ 10 4 cells per well for immunocytochemistry or neurite outgrowth assays.
Upon reaching confluence, the astrocyte monolayers were dosed with varying concentrations of IFN-␥ (1, 10, 50, 100, or 200 units/ml) and/or FGF2 (5 ng/ml) in DMEM/10% FCS for 8 days. The medium was changed every 48 h since cytokines begin to lose activity in our culture systems after 2-3 days (32) . Control cells were maintained under similar conditions without the addition of cytokines. For the mitogen-activated protein kinase (MAPK) experiments, confluent monolayers were maintained in a chemically defined medium, DMEM/ F12 (1/1 v/v) for 4 days, changing the medium every day. On day 4, cytokines as noted above were added to the medium for 30 min, after which time cell extracts were prepared.
[ 3 H]Thymidine incorporation. Astrocytes were subcultured onto 96-well plates (Falcon) at a density of 1.0 ϫ 10 4 cells/well in DMEM/10% FCS for 48 h. The cells were then washed three times with PBS and incubated in serum-free, chemically defined N2 medium (5) for an additional 24 h. Afterward, the cultures were exposed to varying concentrations of IFN-␥ either in serum-free, 5% FCS-containing, or in FGF2 (5 ng/ml)-containing media for 24 h; cells were pulsed for the final 6 h with [methyl-3 H]thymidine (1.0 µCi/ml). The reaction was stopped by aspiration of the incubation solution and washing with PBS three times. Cells were then dislodged by treatment with 0.025% trypsin in 1 mM EDTA and harvested onto Whatman filter paper using a semiautomatic cell harvesting apparatus (Brandel Model 24V, Gaithersburg, MD), and total radioactivity was determined by scintillation counting on a LKB Rackbeta beta-counter (LKB, Turku, Finland).
Cell extracts and Western blotting of ECM molecules. Cellular extracts were prepared by lysing and scraping cells in homogenization buffer consisting of 1% sodium dodecyl sulfate (SDS), 8% sucrose, 2 mM ethylenediaminetetraacetate, 3 mM ethylene glycol-bis(␤-aminoethylether)-tetraacetate, and 50 mM phosphate buffer (pH 8.0). Protein concentrations were determined using the Bio-Rad DC protein assay. Laemmli sample buffer (5ϫ) was added to the extracts and the samples were heated to 100°C for 5 min. Equal protein amounts of cell extracts (30 µg for tenascin and laminin; 10 µg for fibronectin) were subjected to 6% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (23) and then transferred to nitrocellulose (40 mA, 15 h) (51) . The blots were incubated in blocking solution containing 5% dry milk (Carnation brand) in Trisbuffered saline (TBS; 20 mM Tris-HCl, pH 7.5, 0.5 M NaCl) for 2 h and then incubated overnight in a solution of primary antibody (rabbit anti-tenascin; rabbit anti-fibronectin; rabbit anti-laminin) diluted 1:1000 in blocking solution at 4°C. The blots were then washed three times (15 min per wash) in TBS containing 0.05% Tween 20 and incubated with alkaline phosphataseconjugated goat anti-rabbit IgG (Sigma Chemical Co.) at a 1:1000 dilution in 3% dry milk/TBS for 2 h at room temperature. The blots were washed again three times as above and labeled protein was detected colorimetrically using 5-bromo-4-chloro-3-indoyl-phosphate and nitroblue tetrazolium. Immunoblots were scanned at 600 dots per inch and 256-gray-scale resolution on a Microtek 600G scanner. Relative levels of protein expression were determined by analyzing the pixel intensity of the bands using the NIH Image program (Version 1.57, available by anonymous FTP from zippy.nimh.nih.gov) and normalized to percentage of control. The results were examined by one-way ANOVA for statistical significance.
Western blotting for MAPK and phosphotyrosine. Cellular extracts were prepared by lysing and scraping cells in Laemmli sample buffer (1ϫ) with 2 mM Na 3 VO 4 (50) . The samples were heated to 100°C for 5 min. Equal protein amounts were size separated by 12.5% SDS-PAGE and then transferred to nitrocellulose paper (40 mA, 15 h). Blots for phosphotyrosine were incubated in blocking solution containing 1% bovine serum albumin in a modified TBS (10 mM Tris-HCl, pH 7.5, 100 mM NaCl) with 0.1% Tween 20 for 2 h and then incubated 1 h in a solution of RC20H diluted 1:2000 in blocking solution at room temperature. The blots were then washed three times (15 min per wash) in modified TBS and immunoreactive bands were revealed by enhanced chemiluminescence (ECL) according to the manufacturer's instructions. Following ECL, blots were incubated in a stripping buffer consisting of 1% SDS and 100 mM DTT in TBS at 37°C for 1 h. The blots were then washed three times (15 min per wash) in TBS and then incubated in blocking solution containing 5% dry milk (Carnation brand) in TBS for 2 h. Afterward, the blots were incubated overnight in a solution of mouse anti-MAPK diluted 1:1000 in blocking solution at 4°C. The blots were then washed three times (15 min per wash) in TBS containing 0.05% Tween 20 and incubated with alkaline phosphataseconjugated goat anti-mouse IgG (Sigma Chemical Co.) at a 1:000 dilution in 3% dry milk/TBS for 2 h at room temperature. The blots were washed again three times and labeled protein was detected colorimetrically using 5-bromo-4-chloro-3-indoyl-phosphate and nitroblue tetrazolium.
Neuronal cultures and neurite outgrowth assays. Primary dissociated cortical neurons were prepared as previously described (53) . Briefly, timed-pregnant Sprague-Dawley rats were sacrificed at embryonic day 17 (E17), and embryos were removed by Caesarian section. The cerebral cortex was dissected from each embryonic brain, the meningeal tissue was carefully removed, and the cortex was finely minced into sections (Ͻ0.5 mm) with sharp dissecting knives. The sections were placed into cold BME-Hepes and incubated with 0.025% trypsin (type-II) and 0.1% type-IV collagenase for 30 min at 37°C. The reaction was halted with 0.025% soybean trypsin inhibitor and 0.05% DNase I, and the tissue was gently triturated several times through a fire-polished Pasteur pipette. The cells were filtered through sterile 40-µm mesh, resuspended in DMEM/10% FCS, and plated at a density of 2.5 ϫ 10 5 cells/well on top of astrocyte monolayers for neurite outgrowth experiments. Neurite outgrowth was determined using an assay based upon the vital dye 5(6)-carboxyfluorescein diacetate (CFDA) (39) . Mixed neuronal-astrocyte cultures were washed once with Hepes-buffered saline solution (HBS; 122 mM NaCl, 3.3 mM KCl, 1.2 mM CaCl 2 , 0.4 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 10 mM glucose, 25 mM Hepes, pH 7.3) and incubated with 10 µM CFDA in HBS for 15 min at 37°C in 95%:5% air:CO 2 atmosphere with 100% relative humidity, protected from light. Under these conditions, both astrocytes and neurons take up and cleave CFDA to the anionic fluorophore carboxyfluorescein (CF) by the activity of endogenous cellular esterases. The medium was then aspirated and cells were incubated with HBS for 30 min as a rinse, during which astrocytes pump CF into the medium, while neurons retain it for hours. After rinsing, the coverslips were inverted and mounted within a ring of vacuum grease on a glass slide in a drop of HBS. The coverslip was viewed under fluorescein epifluorescence, and images were captured using a Dage CCD72 camera, a Dage DSP2000 digital signal processor (capable of on-chip integration for low-light situations), and a Macintosh Quadra 700 with a Scion LG-3 frame grabber board. Images of labeled neurons were analyzed using NIH Image software to determine the number and length of primary processes of 60 neurons chosen in random fields. The lengths of individual neurites were summed to yield the total neurite length for each neuron. Total lengths were then used to create a distribution curve for each condition and were compared via the Kolmogorov-Smirnov test for significance.
Immunohistochemistry. Cytokine-treated monolayers on glass coverslips were incubated with rabbit polyclonal anti-tenascin, anti-laminin, or anti-fibronectin antibodies diluted 1:100 in 0.1 M PBS containing 0.1% sodium azide (PBS-azide) and 10% FCS (PBSazide serum) for 30 min at 4°C. After being rinsed in PBS-azide, the coverslips were incubated with fluorescein-conjugated goat anti-rabbit secondary antibodies (Jackson Immunologicals) for 30 min at 4°C. The cells were then rinsed again and fixed with ice-cold ethanol/ acetic acid (95/5) for 8 min at 0°C. After rinsing in PBS-azide, the coverslips were mounted in a glycerolcontaining 1,4-diazobicyclo-(2,2,2)-octane to prevent fluorescent fading (22) and sealed with nail enamel. Sections were examined using a Zeiss Axioplan microscope equipped with an epifluorescence illuminator with fluorescein and rhodamine filters. Images were captured using NIH Image software and further processed using Adobe Photoshop software. Final prints were produced using a Kodak XL-7700 color printer.
RESULTS
Effects of IFN-␥ on astrocyte proliferation.
Following 24 h of serum deprivation, rat cortical astrocytes were exposed to murine IFN-␥ in medium containing 5% FCS, serum-free N2 medium, or N2 medium supplemented with 5 ng/ml FGF2 for 24 h and pulsed with [ 3 H]thymidine during the final 6 hours. IFN-␥ treatment of the cells maintained in serum-free medium demonstrated a dose-dependent decrease in [ 3 H]thymidine incorporation compared to untreated controls with an approximately 40% decrease observed at a IFN-␥ concentration of 100 U/ml (Fig. 1) . The highest concentration of IFN-␥ used (1000 U/ml) did produce some further inhibition of [ 3 H]thymidine incorporation to approximately 50% of control (data not shown), but as this concentration is well above physiological levels, further experiments were conducted with 100 U/ml as the maximum dose. Addition of FCS or FGF2 to N2 medium caused significant increases in [ 3 H]thymidine incorporation after 24 h compared to cells maintained in N2 medium alone. Cells incubated with 5% FCS displayed a 500% increase in DNA synthesis compared to those maintained in serum-free medium, while FGF2-treated cultures showed a 300% increase over controls. The effects of these mitogenic agents could be antagonized by IFN-␥ in a dose-dependent manner (Fig. 1) . To determine whether these data reflect a direct effect on cell proliferation rather than cell loss due to the potential toxicity of IFN-␥, we evaluated the incorporation of bromodeoxyuridine (BrdU) into astrocytes, since BrdU can be used to visualize proliferating cells. The alteration in the percentage of BrdU ϩ cells was similar to the alterations in [ 3 H]thymidine incorporation after cytokine treatment (data not shown). Thus, IFN-␥ was not toxic to astrocytes at the concentrations utilized in this experiment and caused a concentration-dependent decrease in cell proliferation, in agreement with previous studies using murine cells (55) . These results suggest that murine IFN-␥ is biologically active toward rat astrocytes and is able to antagonize the mitogenic actions of FGF2 and serum.
Effects of IFN-␥ on tenascin, laminin, and fibronectin production by astrocytes. Confluent astrocyte monolayers in serum-containing medium were exposed to various concentrations of IFN-␥ (1, 10, 50, 100, or 200 U/ml) for 8 days since this allows for pronounced effects to be observed (32) . Afterward, cell extracts were prepared, and proteins were resolved by 6% SDS-PAGE. Gels were transferred to nitrocellulose and probed with antibodies to the ECM proteins tenascin, laminin, or fibronectin. The Western blot with the tenascin polyclonal antibody revealed three polypeptide bands in each lane with M r of 190,000, 200,000, and 240,000. These bands reflect the size of the splice variants of the hexabrachion molecule, in agreement with molecular sizes previously reported for rat tenascin (8) . The laminin polyclonal antibody recognized a polypeptide band of M r 215,000, which corresponds to the B1 chain of laminin, while the antibody to fibronectin recognized a polypeptide of M r 230,000 (Fig. 2) . The Western blots revealed a dose-dependent decrease in the levels of all three splice variants of tenascin after treatment with IFN-␥ (Fig. 2) . These alterations were quantified by scanning densitometry as previously reported (32) . Tenascin production was reduced in a dose-dependent manner to approximately 46% of control levels at a IFN-␥ concentration of 100 U/ml (Table 1) , whereas higher concentrations failed to produce any further reductions in tenascin levels (data not shown). This same trend was also observed with laminin and fibronectin. Quantification of the Western blots showed that laminin levels decreased to 46% of control at the maximal effective concentration (100 U/ml) of IFN-␥ examined (Table 1) . Fibronectin levels appeared to 
FIG. 2.
IFN-␥ reduces astrocytic expression of ECM molecules. In one representative experiment of seven independent experiments, protein extracts from IFN-␥-treated astrocyte monolayers were resolved by 6% SDS-PAGE, transferred to nitrocellulose, and probed with anti-tenascin, anti-laminin, or anti-fibronectin antibodies. Bound antibody was detected using alkaline phosphatase-conjugated secondary antibodies and the NBT/BCIP visualization system. slightly rise with low concentrations of IFN-␥ but declined with higher IFN-␥ concentrations, reaching a maximal reduction of 30% of control at 100 U/ml. One-way ANOVA confirmed that IFN-␥ treatment causes a concentration-dependent decrease in the expression of tenascin, fibronectin, and laminin by cultured astrocytes (P Ͻ 0.001).
IFN-␥ antagonizes the effects of FGF2 on tenascin production. It is our hypothesis that the ECM composition of a glial scar is the net effect of various interactions of cytokines upon astrocytes. The cytokine FGF2 has been previously reported to upregulate tenascin expression on astrocytes (32) . We therefore examined the effects on ECM levels by cotreatment of astrocyte monolayers with the concentration of FGF2 at which maximal tenascin production was observed (5 ng/ml) in combination with various concentrations of IFN-␥ (1, 10, 50, and 100 U/ml). After 8 days of incubation with cytokines, cell extracts were analyzed by Western blotting for their expression of matrix molecules; probing for tenascin, laminin, and fibronectin revealed band sizes similar to that observed when examining extracts from IFN-␥-treated cells. In confirmation of our previous results (32), treatment with FGF2 caused an increase in all three isoforms of tenascin with a slight rise in fibronectin and laminin expression compared to controls (Fig. 3) . Cotreatment with a low concentration (1 U/ml) of IFN-␥ with FGF2 displayed a small degree of synergism in the expression of tenascin levels, but increasing concentrations of IFN-␥ antagonized the effects of FGF2, reducing tenascin levels to 76% of controls (Table 2) . A similar trend was seen for laminin and fibronectin. The levels of both of these molecules displayed a modest increase following treatment with both FGF2 and the lowest concentration of IFN-␥ (1 U/ml), but laminin and fibronectin expression fell as the concentration of IFN-␥ was increased. These changes in the levels of ECM were similar to astrocytes exposed only to IFN-␥. These results suggest that cytokines interact to create an ECM that is distinct from that induced by each cytokine alone.
Immunocytochemistry of ECM molecules. To evaluate whether the alterations in ECM molecules observed in Western blotting of cytokine-treated astrocyte mono- a Confluent astrocyte monolayers were treated with cytokine for 8 days at the concentrations indicated. Cell extracts were subjected to immunoblotting as shown in Fig. 2 . Immunoblots were scanned at a resolution of 600 dpi, and the intensities of the bands were analyzed by NIH Image gel analysis macroroutine. Relative intensities were calculated as a percentage of control from six independent experiments. The levels of each molecule were significantly decreased by IFN-␥ (P Ͻ 0.001, one-way ANOVA).
FIG. 3. Effects of IFN-␥ on FGF2-induced expression of extracellular matrix molecules by astrocytes.
In one representative experiment of six independent experiments, protein extracts from cytokinetreated astrocyte monolayers were resolved by 6% SDS-PAGE, transferred to nitrocellulose, and probed with anti-tenascin, antilaminin, or anti-fibronectin antibodies. Bound antibody was detected using alkaline phosphatase-conjugated secondary antibodies and the NBT/BCIP visualization system. a Confluent astrocyte monolayers were treated with cytokine for 8 days at the concentrations indicated. Relative protein levels from seven independent experiments were calculated as in Table 1 . Treatment with bFGF significantly elevated tenascin levels but not laminin or fibronectin. Levels of all three molecules were significantly decreased by increasing concentrations of IFN-␥ (P Ͻ 0.001, one-way ANOVA).
layers were a reflection of cell surface protein, cytokinetreated monolayers (Ͼ95% GFAP ϩ ) were labeled with antibodies against ECM molecules. The ECM staining for tenascin, laminin, or fibronectin was performed on living, unfixed cultures. Astrocytes maintained under control conditions (DMEM ϩ 10% FCS) demonstrated slight tenascin immunoreactivity that appeared punctate and restricted to the cellular periphery (Fig. 4A) . In addition, the ECM of control monolayers also displayed robust staining of laminin and fibronectin organized into thick fibrillary deposits (Figs. 4B and 4C) .
Treatment of astrocytes with FGF2 for 8 days resulted in a marked increase in tenascin immunoreactivity (Fig. 4D) , while staining of laminin and fibronectin displayed the same intensity and organization as seen in controls (Figs. 4E and 4F ). Exposure to IFN-␥ (100 U/ml) for 8 days resulted in visible changes in all three ECM molecules: tenascin staining appeared punctate and barely visible (Fig. 4G) , while laminin and fibronectin immunoreactivity were also substantially reduced and no longer appeared as fibrils, but rather as punctate deposits (Figs. 4H and 4I) FGF2 and IFN-␥ (Fig. 4J) reduced the robust tenascin immunoreactivity seen in astrocytes treated with FGF2 alone to levels comparable to control monolayers. Additionally, cotreatment reduced the pattern of laminin (Fig. 4K) and fibronectin (Fig. 4L ) immunoreactivity similarly to that seen in cultures treated with IFN-␥ alone, such that extensive fibrils were no longer apparent. The results suggest that the reduction in protein levels seen in Western blots of ECM molecules is a reflection of protein levels on the surface of astrocyte monolayers.
IFN-␥ does not interfere with FGF receptor signal transduction. Activation of cytokine receptors results in a cascade of intracellular events involving many signal transduction pathways. Binding of FGF2 to its receptor (FGFR) results in the phosphorylation of the receptor itself as well as several different downstream molecules, including MAPK, whose targets are transcription factors controlling gene expression (17) . The interferon receptor family utilizes cytoplasmic tyrosine kinases in the JAK-STAT pathway, ultimately activating other transcriptional signals. Given these parallel pathways, we sought to determine if IFN-␥ was antagonizing FGF2-induced receptor signal transduction. We therefore examined the phosphorylation state of MAPK in astrocytes as a marker for FGFR activation after FGF2 treatment or after treatment with both FGF2 and IFN-␥. If IFN-␥ failed to alter the phosphorylation state of MAPK in FGF2-treated astrocytes, this would indicate that the FGFR was functional and that antagonism is occurring further downstream of MAPK, suggesting a possible transcriptional mechanism or that other pathways may be involved and could potentially be disrupted by IFN-␥ signaling. We utilized the technique of Tournier et al. (50) based upon their study demonstrating MAPK phosphorylation following FGF2 treatment in astrocytes. Confluent astrocyte monolayers were maintained in serum-free, chemically defined medium (DMEM/F12, 1/1 v/v) for 4 days, after which time cytokine was added for 30 min. Cell extracts were then subjected to Western blotting with antibodies directed against phosphotyrosine and afterward the blots were stripped and probed for MAPK. Antiphosphotyrosine Western blots revealed multiple bands with an intense band at M r 44,000 (arrowhead) in the FGF2-treated sample, which was barely visible in the control sample or in samples treated with IFN-␥ (Fig.  5) . This band has been previously reported to correspond to MAPK (50) . The intensity of this band was not diminished in cells that were treated with both FGF2 and IFN-␥, suggesting that IFN-␥ does not interfere with FGFR signal transduction down to the level of MAPK phosphorylation. Stripping of the blots and Western blotting with a monoclonal antibody directed against MAPK revealed a single band of M r 44,000 of equal intensity in all samples (Fig. 5) . These results suggest IFN-␥ does not alter FGFR activity and that antagonism may possibly occur downstream of MAPK phosphorylation or in a separate pathway.
Cytokine treatment of astrocytes alters their ability to support neurite outgrowth. Given that the levels of various ECM molecules can have a profound effect on neurite growth behavior in ex vivo culture preparations (14, 18, 44) , we chose to investigate if cytokine-treated astrocyte monolayers could differentially support neurite extension. Confluent astrocyte monolayers were treated with FGF2 (5 ng/ml), IFN-␥ (100 U/ml), or a combination of FGF2 and IFN-␥ for 8 days, replenishing the culture medium and cytokine every 48 h. The monolayers were then rinsed three times with cytokinefree medium to ensure the removal of residual-free, unbound cytokines, and dissociated embryonic cerebral cortical neurons were then added. Twenty-four hours later, the extent of neurite outgrowth was determined and the sum of all the lengths of individual neurites for each neuron was then used to create a distribution curve of total neurite length for each condition. These data are presented in box and whisker plots, where the box encloses the 25th and 75th percentiles of each distribution bisected by the median and the whiskers FIG. 5. IFN-␥ does not interfere with FGF2 signal transduction down to the level of MAPK phosphorylation. In one representative experiment of three independent experiments, cell homogenates from cytokine-treated astrocyte monolayers were resolved by 12.5% SDS-PAGE, transferred to nitrocellulose, probed with anti-phosphotyrosine (RC20), and visualized using ECL. Afterward, the blots were stripped, probed with anti-MAPK antibodies, and detected using alkaline phosphatase-conjugated secondary antibodies and the NBT/ BCIP visualization system. indicate the 5th and 95th percentiles (Fig. 6) . IFN-␥-pretreated monolayers did not differ from controls in their ability to support neurite outgrowth, whereas FGF2-pretreated cells significantly facilitated neurite extension. This dramatic facilitation of neurite outgrowth on FGF2-pretreated monolayers was overcome by the simultaneous administration of IFN-␥. In one representative experiment, the median total neurite length of neurons plated on IFN-␥-treated astrocytes was 149 µm after 24 h, whereas the length of neurons on control monolayers was 147 µm. However, neurons plated on FGF2-pretreated astrocyte monolayers had a statistically significant longer mean total neurite length of 212 µm. Cotreatment of astrocytes with IFN-␥ and FGF2 resulted in monolayers that supported neurons with a mean total neurite length of 143 µm, which was not significantly different from control levels. These observations demonstrate that cytokines can act individually and in combination to both alter astrocyte ECM production and the ability of astrocytes to support neurite outgrowth.
DISCUSSION
The findings presented in this study demonstrate that FGF2 and IFN-␥ interact to modulate astrocyte proliferation and ECM expression, as well as the ability of astrocyte monolayers to regulate neurite outgrowth. Both FGF2 and IFN-␥ are thought to play a role in the response to injury in the CNS, thus suggesting that similar interactions of these molecules on astrocytes may take place after CNS injury, contributing to the formation of the glial scar.
Among the earliest responses following acute trauma to the CNS, with a disruption of the blood-brain barrier, is the recruitment and activation of hematogenous inflammatory cells along with intrinsic microglia (25, 38) . In addition to clearing debris and dying tissue, these cells provide a rich source of multiple cytokines which may interact to orchestrate a wound-healing response (34) . T lymphocytes are one of the subsets of blood-borne cells that enter a CNS injury. T cells release large quantities of IFN-␥ and interleukins; the cytokines in turn activate macrophages and microglia to secrete additional cytokines (4), including IFN-␥, which can thus perpetuate itself in a feedback loop. It has been hypothesized that these inflammatory cytokines also promote astrogliosis (13, 15, 26, 54) . This notion is supported by studies in which administration of IFN-␥ into the site of CNS trauma increases astroglial reactivity more than that induced by trauma alone (54) . Additionally, application of IFN-␥ into a cortical stab wound of neonatal mice, which do not normally exhibit astrogliosis, demonstrated extensive astroglial reactivity as judged by increased GFAP immunoreactivity (3). The hypothesis that IFN-␥ is involved in the pathophysiology of CNS injury seems plausible since we have observed a reduction in cellular proliferation and immunoreactivity of inducible nitric oxide synthase following a stab wound injury to the cerebral cortex of mice with a genetically engineered knockout of the receptor for IFN-␥ (57). The fact that IFN-␥ reduced astrocyte proliferation in culture is also consistent with the low rate of glial proliferation following injury (13, 35) . However, it has been recently demonstrated that levels of IFN-␥ transcript were low to undetectable by RT-PCR following a nitrocellulose stab wound injury to an adult mouse brain (45) , but this does not preclude the presence or activity of IFN-␥ in different pathological states and at other time points. Thus, it appears that while the addition of exogenous IFN-␥ can augment gliosis, its presence is not necessary for the initiation of gliosis, suggesting that other factors are the major participants in mediating this response.
FGF2 is an additional macrophage secretory product that has prominent actions to alter astrocyte physiology. A transient increase in FGF2 mRNA around a lesion site has been demonstrated by in situ hybridization (28) , with levels peaking after approximately 7 days after lesioning and thereafter falling back to control levels. A similar increase in FGF2 protein levels has been found after spinal cord injury (36) . In conjunction with elevated protein levels, an increase in FGF receptor levels on astrocytes has been reported (43) suggesting that the astrocyte may be a primary target   FIG. 6 . Neurite outgrowth on cytokine-treated astrocyte monolayers. In one representative experiment of five independent experiments, E17 cortical neurons were plated on astrocyte monolayers and allowed to extend processes for 24 h. Outgrowth was analyzed and box-and-whisker plots show the distributions of total neurite length for each condition. Boxes enclose the 25th and 75th percentiles of the distribution and are bisected by the median; whiskers indicate the 5th and 95th percentiles. Neurite process outgrowth was significantly increased on FGF2-treated astrocyte monolayers compared to untreated monolayers (Kolmogorov-Smirnov test, *P Ͻ 0.01), while IFN-␥ was able to significantly antagonize this effect (K-S test, †P Ͻ 0.01).
of FGF2 after injury. Previous results demonstrated that FGF2 is a potent mitogen (37, 40) and also alters ECM production by cultured astrocytes (32) . Our results clearly demonstrate that IFN-␥ can antagonize the astrocytic response to FGF2. This antagonism was demonstrated in three different assays: astrocyte proliferation, ECM production, and neurite outgrowth. Despite the potent mitogenic ability of FGF2, a low level of astrocyte proliferation is normally observed following injury (13, 35) . Thus, the mitogenic actions of FGF2 must be antagonized by other factors; we suggest that IFN-␥ is one such factor. On the other hand, ECM production by astrocytes is generally increased after injury, suggesting that the modulation action of IFN-␥ is not sufficient to overcome other stimulatory cytokines. For example, we have observed that the combination of FGF2, TGF-␤, and interleukin-1␤ causes a larger increase in tenascin and fibronectin production by cultured astrocytes than is achieved by any one of these cytokines alone (16) . With respect to neurite outgrowth, FGF2 treatment enhances the ability of cultured astrocytes to support neurite outgrowth, whereas IFN-␥ treatment is without effect. Astrocytes simultaneously treated with both FGF2 and IFN-␥ are similar in their ability to support neurite outgrowth as control cultures.
While the levels of three ECM molecules were substantially reduced on IFN-␥-treated monolayers, neurite outgrowth remained unaltered. Thus, it is likely that a critical amount of growth-signaling molecules was present on the monolayers to facilitate neurite extension, and since the relative ratios between the ECM molecules remained constant the same amount of outgrowth was produced compared to controls. Enhanced neurite outgrowth on FGF2-treated astrocytes may be due to the presence of elevated levels of tenascin, since we have recently shown that binding of purified tenascin to astrocytes enhances neurite outgrowth in our culture system (31) . However, other evidence suggests that tenascin may be inhibitory to regeneration. For example, the process outgrowth of embryonic dopaminergic neurons plated on the surface of adult wounded striatal explants is increased following application of anti-tenascin antibodies (18) . Thus, upregulation of other neurite growth-promoting molecules or down-regulation of inhibitory ones may be the underlying cause for the observed enhancement of neurite outgrowth on astrocytes. Further studies are clearly needed to determine the role of tenascin in either promoting or inhibiting regeneration. Nevertheless, while IFN-␥ did not cause astrocytes to become refractory to neurite outgrowth like the area of the glial scar in vivo, IFN-␥ was ultimately able to overcome the beneficial effects of FGF2-treated astrocytes on neurite outgrowth. This suggests that IFN-␥ can contribute the to the nonpermissive environment of the glial scar.
Binding of FGF2 to its receptor induces oligomerization of receptors, resulting in increased interaction of cytoplasmic kinase domains and receptor autophosphorylation (52) . Intracellular substrates then associate with and are phosphorylated by the activated receptor tyrosine kinase. These substrates include phospholipase C-␥1, GTPase-activating protein, and the putative regulatory subunit of phosphatidylinositol 3Ј-kinase (7) . MAPK is the penultimate member of one pathway, which then phosphorylates transcription factors leading to the activation of transcriptionally regulated genes (17) . IFN-␥ signaling relies on an entirely separate pathway: the IFN-␥ receptor lacks intrinsic kinase activity and relies upon the activation of a cytoplasmic family of tyrosine kinases, the Janus kinases (JAKS). The activated JAKS in turn phosphorylate signal transducers and activators of transcription (STATS), which bind to regulatory elements in promoters of various genes via a IFN-␥ activation site (GAS) (10) . Since IFN-␥ antagonized several actions of FGF2, we hypothesized that these signals may converge. Since MAPK phosphorylation induced by FGF2 was not altered by IFN-␥, this suggests that the modulation may take place further downstream, i.e., at the level of transcriptional regulation.
Examination of the fibronectin and tenascin promoters reveal a common sequence that corresponds to the consensus sequence for GAS sites (TTNCNNNAA), suggesting that activated STAT1␣ may be able to bind and regulate ECM genes. Thus, FGF2 signaling may be transcriptionally activating tenascin expression, which can then be inhibited by the binding of STAT1␣ to a regulatory site that prevents transcription. This scenario is analogous to a recent report that demonstrated that IFN-␥ can downregulate nerve growth factor (NGF) production by a human glioblastoma cell line through the binding of STAT1␣ to a regulatory site in the NGF promoter (1) . This report also demonstrated that IFN-␥ antagonized IL-1␤ stimulation of NGF production, possibly due to interference with the binding of the IL-1 ␤-activated transcription factor NF-B. Preliminary gel-shift experiments demonstrate that the consensus GAS element within the fibronectin promoter can, in fact, bind transcriptional factors from IFN-␥-treated COS cell lysates, which could explain the enhanced production of fibronectin following IFN-␥ treatment of primary fibroblast cultures (9) . However, we have not yet been able to identify similar activity in astrocyte lysates, suggesting that astrocytes may lack additional transcriptional factors necessary for binding to this potential GAS element. Alternatively, other STAT1␣-induced downstream regulatory factors or their cellular biochemical responses could be altering the activity of specific control regions within these ECM genes. It therefore seems plausible that interaction of cytokineactivated transcriptional signals can ultimately serve to dictate the physiological properties of astrocytes after CNS trauma.
We have demonstrated a significant interaction between FGF2 and IFN-␥ on astrocyte physiology. These data reinforce the fact that the glial scar is a result of the interactions of many different cytokines acting in temporally and spatially distinct patterns. One way of facilitating regeneration in the adult CNS may be to enhance the survival of neurons and their processes through trophic support and to create a permissive environment that facilitates neurite outgrowth through the lesion site. Understanding the role of the cytokines expressed after injury, both individually and in combination, may be a key to attaining this delicate balance of growth. With this knowledge, it may be possible to selectively inhibit the detrimental activities while fostering the salutary ones, thus enhancing regeneration and recovery of function following injury.
